The Team Advancing the Science

Replimune has assembled a world-class team who together pioneered the development of the first FDA-approved oncolytic immunotherapy. Supported by scientists, clinicians and advisors, we are working to advance the field by developing a new generation of optimally designed, potent oncolytic immunotherapies to treat a broad range of cancers.